COLUMBIA, Md., Oct. 2, 2025 /PRNewswire/ — The Maryland Stem Cell Research Commission (the Commission) awarded $4,707,142 in grant funding to accelerate the development of innovative stem cell–based therapies. The Maryland Stem Cell Research Fund (MSCRF), overseen by the Commission, is an independent program within TEDCO designed to promote human stem cell research and treatments through grants to entities in Maryland.
The first round of funding for fiscal year 2026 will support 11 projects targeting a wide range of conditions including neurodegenerative, bone and cartilage, heart, developmental and vision disorders. Grants went to academic institutions such as Johns Hopkins University and the University of Maryland, Baltimore County, as well as to pioneering regenerative medicine companies including Nanochon, Inc.; REPROCELL U.S.A., Inc.; RoosterBio, Inc.; HOHCells, LLC; Theradaptive, Inc.; and Stemora, Inc.
“Maryland’s regenerative medicine community continues to make headway in developing therapies for debilitating diseases like sickle cell disease and acute graft versus host disease, and in advancing innovations in areas such as bone growth and cartilage regeneration,” said Ruchika Nijhara, Ph.D., executive director of the MSCRF. “The MSCRF is proud to support groundbreaking work that has the potential to transform patient care and strengthen our state’s leadership in regenerative medicine. These awards not only accelerate scientific discovery but also foster collaboration, innovation and economic growth across Maryland’s life sciences ecosystem. The MSCRF grants serve as a critical financial lifeline for regenerative medicine researchers and companies in Maryland and many supported therapies are already showing promise in clinical development.”
Full story: Maryland Stem Cell Research Fund Awards $4.7 million to Support Innovations in Stem Cell Research – BioSpace
